Discontinuing imatinib in chronic myeloid leukemia: Don't try this at home

Leukemia and Lymphoma

Volumn 50, Issue 6, 2009, Pages 868-870

  Mattison, Ryan ^a   Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; INTERFERON;

CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLUID RETENTION; HUMAN; LEUKEMIA REMISSION; MUSCLE CRAMP; NOTE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 68449101746     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902934951     Document Type: Note

References (9)

1. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
2. Hochhaus A, Kantarjian HM, BaccaraniM, Lipton JH, Apperly JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-2309.
3. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-3546.
4. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009 March 12 [Epub ahead of Print].
5. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809-1820.
6. Goh H-G, Kim Y-J, Kim D-W, Kim H-J, Kim S-H, Jang S-E, et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: Implication for intermittent imatinib therapy. Leuk Lymphoma 2009;50:944-951.
7. Ross DDM, Grigg A, Schwarer A, Arthur C, Loftus K, Mills AK, et al. The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early. ASH Ann Meeting Abstr 2008;112:1102.
8. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109: 58-60.
9. Mahon F-X, Huguet F, Guilhot F, Legros L, Nicolini F, Charbonnier A, et al. Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French pilot study and first results from the multicentre ≪ Stop imatinib ≫ (STIM) Study. ASH Ann Meeting Abstr 2008;112:187.